Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimalarial polyamine analogues.

M L Edwards1, D M Stemerick, A J Bitonti

  • 1Merrell Dow Research Institute, Cincinnati, Ohio 45215.

Journal of Medicinal Chemistry
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.

Journal of thrombosis and haemostasis : JTH·2014
Same author

DIAGNOSTIC METHODS FOR SEROTONIN AND HISTAMINE ABNORMALITIES.

A listing of research in the cardiovascular field·2014
Same author

PRIMARY MYOCARDIAL DISEASE (HEART MUSCLE DISEASE, CARDIOMYOPATHY).

A listing of research in the cardiovascular field·2014
Same author

Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Amoebic pericarditis.

The Medical journal of Australia·2010
Same author

Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.

Human reproduction (Oxford, England)·2005
Same journal

Development of Indole-3-yl-methylene-thiobarbital Derivatives as Inhibitors of HDAC8 Enzyme Activity.

Journal of medicinal chemistry·2026
Same journal

Discovery of a Potent NAMPT-Targeting PROTAC for the Suppression of Triple-Negative Breast Cancer via Macrophage Reprogramming.

Journal of medicinal chemistry·2026
Same journal

3',4'-Isopropylidene-α-galactosylceramide Enables Multidose Th1 Adjuvanticity Despite Limited Serial Serum IFN-γ Responsiveness.

Journal of medicinal chemistry·2026
Same journal

A Bioorthogonally Cleavable <i>N</i>-Oxide Linker for Prodrug Design: Elucidating the Structure-Cyclization Kinetics Relationships for Controlled Drug Release.

Journal of medicinal chemistry·2026
Same journal

A Melatonin-Catechol Hybrid Molecule Prolongs Lifespan via Regulating ROS and Reprogramming Mitochondrial Metabolism.

Journal of medicinal chemistry·2026
Same journal

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026
See all related articles

Novel tetraamines show potent antimalarial activity against Plasmodium falciparum. A specific compound, when combined with another inhibitor, achieved radical cures in experimental malaria infections in mice.

Area of Science:

  • Medicinal Chemistry
  • Parasitology
  • Drug Discovery

Background:

  • Malaria remains a significant global health challenge, necessitating the development of new antimalarial drugs.
  • Existing treatments face challenges due to drug resistance and side effects.

Purpose of the Study:

  • To synthesize and evaluate a series of novel tetraamines for antimalarial activity.
  • To identify optimal structural modifications for enhanced efficacy against Plasmodium falciparum.

Main Methods:

  • Synthesis of tetraamine analogues with varying chain lengths (x, y) and substituents (R).
  • In vitro testing of synthesized compounds against Plasmodium falciparum growth.
  • In vivo testing of promising compounds against Plasmodium berghei infections in mice.

Related Experiment Videos

Main Results:

  • Dibenzyl tetraamine analogues demonstrated the most potent inhibition of Plasmodium falciparum growth (IC50 ~10(-6) M).
  • Optimal antimalarial activity was achieved with a tetraamine structure featuring y=7 and x=3 chain lengths.
  • Compound 8 (MDL 27,695), a dibenzyl tetraamine with y=7, x=3, in combination with alpha-(difluoromethyl)ornithine, led to radical cures in experimental mouse malaria models.

Conclusions:

  • Novel tetraamines represent a promising class of compounds for antimalarial drug development.
  • Structure-activity relationship studies identified key modifications for improved efficacy.
  • Combination therapy with tetraamines and ornithine decarboxylase inhibitors shows potential for radical malaria cure.